InterCure Ltd.

NASDAQ:INCR

Drug Manufacturers - Specialty & Generic

Healthcare
$3.98 -3.97%

-$0.04 today

Market cap
$51.63M
Beta
0.57
P/E (TTM)
-4.3
EPS (TTM)
-$0.64
52W Low $0.68High $1.77

Volume 0.01M

Average 0.04M

INCR Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

InterCure Ltd.NASDAQ: INCR

Weighted Avg Shares (Diluted) · Q2 FY2025 · quarter ended Jun 2025

Weighted avg shares (diluted) growth accelerates

Q2 FY2025 weighted avg shares (diluted) of 56.8M shares rose 18.9% year over year, ahead of the +8.9% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +7.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +18.9% holds above the trailing-twelve-month pace of +8.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2025
56.8M+0.0% QoQ
Last fiscal yearDec 2025
56.8M+18.9% YoY
LTMJun 2025
50.39M+8.9% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.9%——
1 year+18.9%——
3-year CAGR+7.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
56.8M ILS
Year-over-year change
+18.9%
4-year CAGR
+8.6%

Weighted Avg Shares (Diluted) vs competitors

How INCR compares with its peers on the latest reported figures

  • INCR's LTM Jun 2025 weighted avg shares (diluted) of 50.39M shares is the 5th highest of the 9 companies compared; the peer median is 48.91M shares.
  • Its year-over-year change of +8.9% is the 7th highest of 9, against a peer median of +49.7%.
  • Over three fiscal years its annual growth of +7.8% compares with a peer median of +20.7%.
INCR Competitors Peer median
Weighted Avg Shares (Diluted) for INCR and competitors
Company Period LTM YoY 3-year CAGR
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026107.08M +1045.8%+372.5%
FBIOFortress Biotech, Inc.LTM Mar 202695.09M +349.0%+261.1%
CRDLCardiol Therapeutics Inc.LTM Mar 202694.16M +29.4%+11.6%
BMEABiomea Fusion, Inc.LTM Mar 202656.46M +55.6%+21.3%
INCRInterCure Ltd.LTM Jun 202550.39M +8.9%+7.8%
HYFTMindWalk Holdings Corp.LTM Jan 202641.36M +43.8%+19.2%
CAMPCAMP4 Therapeutics CorporationLTM Mar 202637.54M +102.0%—
AMWLAmerican Well CorporationLTM Mar 202616.27M +6.6%+5.4%
ASRTAssertio Holdings, Inc.LTM Mar 20266.59M +3.5%+20.7%
Peer median (excluding INCR) 48.91M+49.7%+20.7%

Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

ILS
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue219.68M388.68M355.55M238.85M270.2M
Cost of Revenue128.55M233.6M250.46M208.61M237.02M
Gross Profit91.13M155.08M105.1M30.23M33.18M
Gross Margin41.5%39.9%29.6%12.7%12.3%
Research & Development1.24M632K388K414K390K
Selling, General & Admin53.46M97.32M86.24M84.63M80.41M
Operating Expenses62.95M104.46M146.66M97.44M26.45M
Depreciation & Amortization7.39M11.7M13.17M15.37M17.15M
EBITDA31.17M70.23M(23.9M)(51.31M)(7.29M)
EBITDA Margin14.2%18.1%-6.7%-21.5%-2.7%
Operating Income28.19M50.63M(41.57M)(67.21M)6.73M
Operating Margin12.8%13.0%-11.7%-28.1%2.5%
Interest Income130K844K4.55M2.7M1.56M
Interest Expense5.05M14.69M24.22M20.65M19.66M
Other Income / Expenses(9.45M)(6.79M)(19.72M)(20.12M)(50.84M)
Income Before Tax18.74M43.84M(61.29M)(87.32M)(44.1M)
Pre-Tax Margin8.5%11.3%-17.2%-36.6%-16.3%
Income Tax Expense11.44M93K2.25M(14.53M)(7.32M)
Net Income4.69M44.82M(61.96M)(67.8M)(35.71M)
Net Margin2.1%11.5%-17.4%-28.4%-13.2%
EPS (Basic)0.120.99(1.36)(1.42)(0.63)
EPS (Diluted)0.110.99(1.36)(1.42)(0.63)
Weighted Avg Shares38.49M45.35M45.56M47.77M56.8M
Weighted Avg Shares (Diluted)40.84M45.35M45.57M47.77M56.8M

InterCure Ltd.

NASDAQ:INCR

Intrinsic Alpha fair value

Locked

Current Price

$3.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.